Zobrazeno 1 - 10 of 45 pro vyhledávání: '"Isabel Echavarria"'
1
Akademický článek
Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)
Autor: Silvia Antolín Novoa, Santiago Escrivá-de-Romaní, Pablo Tolosa Ortega, Lucía Oliva Fernández, Rafael López López, Ana López González, Pilar de la Morena Barrio, Isabel Echavarria Díaz-Guardamino, José Enrique Alés Martinez, Zita Garate, Lucia González-Cortijo
Publikováno v: Cancer Treatment and Research Communications, Vol 37, Iss , Pp 100772- (2023)
Introduction: Trastuzumab emtansine (T-DM1) significantly improves invasive disease-free survival and reduces the risk of recurrence in patients with HER2-positive early breast cancer (EBC) with residual disease (RD). The KARMA study aimed to describ
Externí odkaz: https://doaj.org/article/9fdeb598f4324f0391f50f42c636b7e1
Zobrazit plný text záznamu
2
Akademický článek
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
Autor: Miguel Martin, Rocio Ramos-Medina, Rebeca Bernat, Jose Angel García-Saenz, Maria del Monte-Millan, Enrique Alvarez, Maria Cebollero, Fernando Moreno, Eva Gonzalez-Haba, Oscar Bueno, Paula Romero, Tatiana Massarrah, Isabel Echavarria, Yolanda Jerez, Blanca Herrero, Ricardo Gonzalez del Val, Nerea Lobato, Patricia Rincon, Maria Isabel Palomero, Ivan Marquez-Rodas, Santiago Lizarraga, Fernando Asensio, Sara Lopez-Tarruella
Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Triple-negative breast cancer (TNBC) is highly responsive to neoadjuvant polychemotherapy regimens including anthracyclines, taxanes, and, more recently, carboplatin. However, there is inadequate information on the individual contribution of
Externí odkaz: https://doaj.org/article/6320cb09619d46bdb0b5fd843bc4c5e3
Zobrazit plný text záznamu
4
SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
Autor: Jose Angel Garcia-Saenz, Isabel Blancas, Isabel Echavarria, Carmen Hinojo, Mireia Margeli, Fernando Moreno, Sonia Pernas, Teresa Ramon y Cajal, Nuria Ribelles, Meritxell Bellet
Publikováno v: Clinical and Translational Oncology.
Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::816beaaa4d222c64a5935761b08c4d5d
https://doi.org/10.1007/s12094-023-03203-8
Zobrazit plný text záznamu
7
How we treat HR-positive, HER2-negative early breast cancer
Autor: Sara Lopez-Tarruella, Isabel Echavarria, Yolanda Jerez, Blanca Herrero, Salvador Gamez, Miguel Martin
Publikováno v: Future Oncology. 18:1003-1022
The present goal of therapy for early HR+/HER2- breast cancer (BC) is to optimize disease-free survival (DFS) and overall survival (OS) rates with the currently available therapies while avoiding any relevant long-term sequalae. Local therapies have
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fd65ea8f4df7bf46328aa9f8935eb12
https://doi.org/10.2217/fon-2021-0668
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje